There are a few key trends to look for if we want to identify the next multi-bagger. In a perfect world, we'd like ...

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Merck (MRK) ended the recent trading session at $117.17, demonstrating a -0.05% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.19%.

In this photo illustration, the Merck & Co., Inc. logo seen displayed on a ... [+] tablet. (Photo Illustration by Igor ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $117.96 which represents a slight increase of $2.10 or 1.81% from the prior close of $115.86. The stock opened at $115.8 and touched a ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $118.59 which represents a slight increase of $2.79 or 2.41% from the prior close of $115.8. The stock opened at $116.61 and touched a ...

Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its ...

Truist Financial analyst Srikripa Devarakonda assigned a Buy rating to the stock today. The company’s shares closed last Friday at ...

Jefferies analyst Akash Tewari maintained a Buy rating on Merck & Company (MRK – Research Report) today and set a price target of ...

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

Thank you for attending our Global Healthcare Conference. Today, I have the pleasure to host Joe Romanelli, President of Human Health International; and Peter Dannenbaum, Head of Investor Relations.

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC. RAHWAY, N.J., September 18, 2024--Merck ...